AVE0991 ameliorates dopaminergic neuronal damage in Parkinson’s disease through HOTAIRM1/miR-223-3p/α-synuclein axis

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
1 Online-Ressource.
Sprache
Englisch

Erschienen in
AVE0991 ameliorates dopaminergic neuronal damage in Parkinson’s disease through HOTAIRM1/miR-223-3p/α-synuclein axis ; volume:14 ; number:1 ; day:1 ; month:11 ; year:2024 ; pages:1-16 ; date:12.2024
Scientific reports ; 14, Heft 1 (1.11.2024), 1-16, 12.2024

Urheber
Duan, Rui
Shi, Liang
Deng, Yang
Wu, Jiang
Wang, Shiyao
Peng, Qiang
Li, Zhongyuan
Xu, Zhaohan
Wang, Feng
Xue, Xue
Gao, Qing
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1038/s41598-024-76058-w
URN
urn:nbn:de:101:1-2501212127108.186323063687
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:22 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Duan, Rui
  • Shi, Liang
  • Deng, Yang
  • Wu, Jiang
  • Wang, Shiyao
  • Peng, Qiang
  • Li, Zhongyuan
  • Xu, Zhaohan
  • Wang, Feng
  • Xue, Xue
  • Gao, Qing
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Models of α-synuclein aggregation in Parkinson’s disease

Models of α-synuclein aggregation in Parkinson’s disease

Thrombomodulin reduces α-synuclein generation and ameliorates neuropathology in a mouse model of Parkinson’s disease

Thrombomodulin reduces α-synuclein generation and ameliorates neuropathology in a mouse model of Parkinson’s disease

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease

Inflammasome inhibition protects dopaminergic neurons from α-synuclein pathology in a model of progressive Parkinson’s disease

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease

α-Synuclein pathology disrupts mitochondrial function in dopaminergic and cholinergic neurons at-risk in Parkinson’s disease

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Dermal α-synuclein oligomers and aggregates in Parkinson’s disease

Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease

Role of Apolipoproteins and α-Synuclein in Parkinson’s Disease

Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model

Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model

Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease

Erythrocytic α-Synuclein as a potential biomarker for Parkinson’s disease

Initiation and progression of α-synuclein pathology in Parkinson’s disease

Initiation and progression of α-synuclein pathology in Parkinson’s disease

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease

GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson’s Disease

Irisflorentin improves α-synuclein accumulation and attenuates 6-OHDA-induced dopaminergic neuron degeneration, implication for Parkinson’s disease therapy

Irisflorentin improves α-synuclein accumulation and attenuates 6-OHDA-induced dopaminergic neuron degeneration, implication for Parkinson’s disease therapy

Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson’s disease

Plasminogen degrades α-synuclein, Tau and TDP-43 and decreases dopaminergic neurodegeneration in mouse models of Parkinson’s disease

Verbundene Objekte